Literature DB >> 20841605

Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Susanne K Kjær1, Kirsten Frederiksen, Christian Munk, Thomas Iftner.   

Abstract

BACKGROUND: Infection with high-risk human papillomavirus (HPV) is the main cause of high-grade cervical intraepithelial neoplasia (CIN) and cancer. It has been suggested that information about high-risk HPV type-specific infection might make cervical cancer screening more effective. Persistent HPV infection could also be a useful screening marker. We estimated the long-term risk of high-grade CIN after one-time detection of high-risk HPV DNA and after persistent infection with individual high-risk HPV types.
METHODS: A cohort of 8656 women from the general population of Denmark was examined twice, 2 years apart (first study examination: May 15, 1991, to January 31, 1993; second study examination: October 1, 1993, to January 31, 1995). The women underwent a gynecological examination and cervical cytology and had swabs taken for HPV DNA analysis by the Hybrid Capture 2 and line probe assays. The women were followed up through the nationwide Danish Pathology Data Bank for cervical neoplasia for up to 13.4 years. The absolute risk of developing cervical lesions before a given time was estimated as a function of time.
RESULTS: For women with normal cytological findings who were concurrently HPV16 DNA positive at the second examination, the estimated probability of developing CIN grade 3 (CIN3) or worse within 12 years of follow-up was 26.7% (95% confidence interval [CI] = 21.1% to 31.8%). The corresponding risks among those infected with HPV18 was 19.1% (95% CI = 10.4% to 27.3%), with HPV31 was 14.3% (95% CI = 9.1% to 19.4%), and with HPV33 was 14.9% (95% CI = 7.9% to 21.1%). The absolute risk of CIN3 or worse after infection with high-risk HPV types other than HPV16, HPV18, HPV31, or HPV33 was 6.0% (95% CI = 3.8% to 8.3%). The estimated absolute risk for CIN3 or cancer within 12 years of the second examination among women who were HPV16 DNA positive at both examinations was 47.4% (95% CI = 34.9% to 57.5%); by contrast, the risk of CIN3 or worse following a negative Hybrid Capture 2 test was 3.0% (95% CI = 2.5% to 3.5%).
CONCLUSION: HPV16, HPV18, HPV31, and HPV33 infection and especially HPV16 persistence were associated with high absolute risks for progression to high-grade cervical lesions. The results indicate the potential value of genotyping in cervical cancer screening. Given that HPV DNA-negative women retained their low risk of CIN3 or worse for many years, frequent screening of these women may be unnecessary.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20841605      PMCID: PMC2950170          DOI: 10.1093/jnci/djq356

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  22 in total

1.  The HPV DNA virus hybrid capture assay: what is it--and where do we go from here?

Authors:  John P Vernick; Carmen K Steigman
Journal:  MLO Med Lab Obs       Date:  2003-03

2.  Regression models for interval censored survival data: application to HIV infection in Danish homosexual men.

Authors:  B Carstensen
Journal:  Stat Med       Date:  1996-10-30       Impact factor: 2.373

3.  The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period.

Authors:  Susanne Kjaer; Estrid Høgdall; Kirsten Frederiksen; Christian Munk; Adriaan van den Brule; Edith Svare; Chris Meijer; Attilla Lorincz; Thomas Iftner
Journal:  Cancer Res       Date:  2006-10-23       Impact factor: 12.701

4.  Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear.

Authors:  Johannes Berkhof; Nicole W J Bulkmans; Maaike C G Bleeker; Saskia Bulk; Peter J F Snijders; Feja J Voorhorst; Chris J L M Meijer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

5.  Development and duration of human papillomavirus lesions, after initial infection.

Authors:  Rachel L Winer; Nancy B Kiviat; James P Hughes; Diane E Adam; Shu-Kuang Lee; Jane M Kuypers; Laura A Koutsky
Journal:  J Infect Dis       Date:  2005-01-21       Impact factor: 5.226

6.  The carcinogenicity of human papillomavirus types reflects viral evolution.

Authors:  Mark Schiffman; Rolando Herrero; Rob Desalle; Allan Hildesheim; Sholom Wacholder; Ana Cecilia Rodriguez; Maria C Bratti; Mark E Sherman; Jorge Morales; Diego Guillen; Mario Alfaro; Martha Hutchinson; Thomas C Wright; Diane Solomon; Zigui Chen; John Schussler; Philip E Castle; Robert D Burk
Journal:  Virology       Date:  2005-06-20       Impact factor: 3.616

7.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

Authors:  Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg
Journal:  Lancet Oncol       Date:  2008-04-11       Impact factor: 41.316

Review 8.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis.

Authors:  Jill Koshiol; Lisa Lindsay; Jeanne M Pimenta; Charles Poole; David Jenkins; Jennifer S Smith
Journal:  Am J Epidemiol       Date:  2008-05-15       Impact factor: 4.897

9.  Comparison of the performance of different HPV genotyping methods for detecting genital HPV types.

Authors:  Stefanie J Klug; Anco Molijn; Betti Schopp; Barbara Holz; Angelika Iftner; Wim Quint; Peter J F Snijders; Karl-Ulrich Petry; Susanne Krüger Kjaer; Christian Munk; Thomas Iftner
Journal:  J Med Virol       Date:  2008-07       Impact factor: 2.327

10.  Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study.

Authors:  Philip E Castle; Ana Cecilia Rodríguez; Robert D Burk; Rolando Herrero; Sholom Wacholder; Mario Alfaro; Jorge Morales; Diego Guillen; Mark E Sherman; Diane Solomon; Mark Schiffman
Journal:  BMJ       Date:  2009-07-28
View more
  172 in total

1.  The value of HPV vaccination.

Authors: 
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

2.  Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage.

Authors:  Long Fu Xi; Mark Schiffman; Laura A Koutsky; Zhonghu He; Rachel L Winer; Ayaka Hulbert; Shu-Kuang Lee; Yang Ke; Nancy B Kiviat
Journal:  Int J Cancer       Date:  2012-07-11       Impact factor: 7.396

3.  Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations.

Authors:  Carole Fakhry; Barbara T Rosenthal; Douglas P Clark; Maura L Gillison
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-11

4.  A Suggested Approach to Simplify and Improve Cervical Screening in the United States.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

5.  Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus types.

Authors:  Denise M Schütze; Peter J F Snijders; Leontien Bosch; Duco Kramer; Chris J L M Meijer; Renske D M Steenbergen
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

6.  Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions.

Authors:  F Bottari; M Sideri; C Gulmini; S Igidbashian; A Tricca; C Casadio; S Carinelli; S Boveri; D Ejegod; J Bonde; M T Sandri
Journal:  J Clin Microbiol       Date:  2015-04-22       Impact factor: 5.948

7.  Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.

Authors:  Van K Morris; Asif Rashid; Miguel Rodriguez-Bigas; Prajnan Das; George Chang; Aki Ohinata; Jane Rogers; Christopher Crane; Robert A Wolff; Cathy Eng
Journal:  Oncologist       Date:  2015-09-17

8.  HPV16 E6*II gene expression in intraepithelial cervical lesions as an indicator of neoplastic grade: a pilot study.

Authors:  Dorota Pastuszak-Lewandoska; Anna Bartosińska-Dyc; Monika Migdalska-Sęk; Karolina H Czarnecka; Ewa Nawrot; Daria Domańska; Krzysztof Szyłło; Ewa Brzeziańska
Journal:  Med Oncol       Date:  2014-01-17       Impact factor: 3.064

9.  Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2.

Authors:  Mark Schiffman; Kai Yu; Rosemary Zuna; S Terence Dunn; Han Zhang; Joan Walker; Michael Gold; Noorie Hyun; Greg Rydzak; Hormuzd A Katki; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2016-10-17       Impact factor: 7.396

10.  Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer.

Authors:  S L Sudenga; S Shrestha
Journal:  Int J Infect Dis       Date:  2013-02-27       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.